These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27583591)

  • 1. Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.
    Moholisa RR; Schomaker M; Kuhn L; Castel S; Wiesner L; Coovadia A; Strehlau R; Patel F; Pinillos F; Abrams EJ; Maartens G; McIlleron H
    Pediatr Infect Dis J; 2016 Dec; 35(12):e378-e383. PubMed ID: 27583591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L
    JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
    Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.
    Moholisa RR; Schomaker M; Kuhn L; Meredith S; Wiesner L; Coovadia A; Strehlau R; Martens L; Abrams EJ; Maartens G; McIlleron H
    Antivir Ther; 2014; 19(4):399-406. PubMed ID: 24518130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
    BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
    Alvarez-Uria G; Pakam R; Naik PK; Midde M
    PLoS One; 2014; 9(9):e108063. PubMed ID: 25232730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
    Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH
    Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.
    Moorthy A; Kuhn L; Coovadia A; Meyers T; Strehlau R; Sherman G; Tsai WY; Chen YH; Abrams EJ; Persaud D
    Clin Infect Dis; 2011 Feb; 52(4):514-21. PubMed ID: 21258105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
    Violari A; Lindsey JC; Hughes MD; Mujuru HA; Barlow-Mosha L; Kamthunzi P; Chi BH; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Purdue L; Eshleman SH; Abrams EJ; Millar L; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P
    N Engl J Med; 2012 Jun; 366(25):2380-9. PubMed ID: 22716976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy.
    Pintye J; Bacchetti P; Teeraananchai S; Kerr S; Prasitsuebsai W; Singtoroj T; Kuncze K; Louie A; Koss CA; Jin C; Phung N; Horng H; Sohn AH; Gandhi M
    J Acquir Immune Defic Syndr; 2017 Dec; 76(4):367-371. PubMed ID: 28825944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?
    Ripamonti D; Hill A; Lauthouwers E; van Delft Y; Moecklinghoff C
    AIDS Rev; 2013; 15(4):230-6. PubMed ID: 24322383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.
    Bellusci CP; Rocco C; Aulicino P; Mecikovsky D; Curras V; Hegoburu S; Bramuglia GF; Bologna R; Sen L; Mangano A
    Gene; 2013 Jun; 522(1):96-101. PubMed ID: 23528223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
    Lindsey JC; Hughes MD; Violari A; Eshleman SH; Abrams EJ; Bwakura-Dangarembizi M; Barlow-Mosha L; Kamthunzi P; Sambo PM; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Zimmer B; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P;
    Pediatr Infect Dis J; 2014 Aug; 33(8):846-54. PubMed ID: 25222305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
    Gondrie IPE; Bastiaans DET; Fraaij PLA; Driessen GJA; van der Knaap LC; Visser EG; van Jaarsveld P; de Groot R; Hartwig NG; Burger DM; van Rossum AMC
    Pediatr Infect Dis J; 2017 Oct; 36(10):976-980. PubMed ID: 28475554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
    HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: a systematic review.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams EJ
    AIDS; 2014 Mar; 28 Suppl 2():S137-46. PubMed ID: 24849473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
    Reitz C; Coovadia A; Ko S; Meyers T; Strehlau R; Sherman G; Kuhn L; Abrams EJ
    J Infect Dis; 2010 Apr; 201(8):1121-31. PubMed ID: 20214476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
    Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L
    Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.